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Abstract MVA-BN
-HER2 is a new candidate immu-
notherapy designed for the treatment of HER-2-positive
breast cancer. Here, we demonstrate that a single treatment
with MVA-BN
-HER2 exerts potent anti-tumor efﬁcacy in
a murine model of experimental pulmonary metastasis.
This anti-tumor efﬁcacy occurred despite a strong tumor-
mediated immunosuppressive environment characterized
by a high frequency of regulatory T cells (Treg) in the lungs
of tumor-bearing mice. Immunogenicity studies showed
that treatment with MVA-BN
-HER2 induced strongly
Th1-dominated HER-2-speciﬁc antibody and T-cell
responses. MVA-BN
-HER2-induced anti-tumor activity
was characterized by an increased inﬁltration of lungs with
highly activated, HER-2-speciﬁc, CD8
?CD11c
? T cells
accompanied by a decrease in the frequency of Treg cells in
the lung, resulting in a signiﬁcantly increased ratio of
effector T cells to Treg cells. In contrast, administration of
HER2 protein formulated in Complete Freund’s Adjuvant
(CFA) induced a strongly Th2-biased immune response to
HER-2. However, this did not lead to signiﬁcant inﬁltration
of the tumor-bearing lungs by CD8
? T cells or the decrease
in the frequency of Treg cells nor did it result in anti-tumor
efﬁcacy. In vivo depletion of CD8
? cells conﬁrmed that
CD8 T cells were required for the anti-tumor activity of
MVA-BN
-HER2. Furthermore, depletion of CD4
? or
CD25
? cells demonstrated that tumor-induced Treg cells
promoted tumor growth and that CD4 effector cells also
contribute to MVA-BN
-HER2-mediated anti-tumor efﬁ-
cacy.Takentogether,ourdatademonstratethattreatmentwith
MVA-BN
-HER2 controls tumor growth through mecha-
nisms including the induction of Th1-biased HER-2-speciﬁc
immune responses and the control of tumor-mediated
immunosuppression.
Keywords Immunotherapy  Modiﬁed Vaccinia Ankara
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Introduction
MVA-BN
-HER2 is currently being developed as a can-
didate for breast cancer immunotherapy and has shown
biological activity in ongoing Phase I clinical trials
(NCT0048277). MVA-BN
-HER2 is a Modiﬁed Vaccinia
Ankara-based recombinant vaccine vector derived from
MVA-BN
 (IMVAMUNE
), a highly attenuated clonal
virus currently in development as a smallpox vaccine [1].
MVA-BN
-HER2 encodes a modiﬁed form of human
epidermal growth factor receptor 2 (HER-2), referred to as
HER2. HER2 comprises of the extracellular domains of
HER-2 and was further modiﬁed to encode two promis-
cuous T helper cell epitopes from tetanus toxin. This
modiﬁcation has been shown to improve its immunoge-
nicity in a tolerant environment [2].
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DOI 10.1007/s00262-011-1077-4Successful cancer immunotherapy will most likely
require the induction of comprehensive innate and Th1
adaptive immune responses that provide effector mecha-
nisms able to directly kill tumor cells while combating
the inﬂammatory/immunosuppressive responses induced
by the growing tumor. In this regard, MVA-BN
 has been
shown to confer protection in animal models of smallpox
through the induction of strong Th1 adaptive as well as
innate immune responses [3–7]. These intrinsic immune
properties are beneﬁcial features to mediate adequate
immune responses to MVA-BN
-encoded transgenes
expressing tumor targets. This was demonstrated herein,
by comparing the induction of HER-2-speciﬁc immune
responses mediated by either MVA-BN
-HER2 or HER2
formulated in Freund’s adjuvant. When tested in a murine
model of experimental pulmonary metastasis (CT26-
HER-2), MVA-BN
-HER2-mediated immune respon-
ses translated into potent anti-tumor efﬁcacy, while
HER2 formulated in Freund’s adjuvant had only modest
effects.
Multiple cell types can exert immunosuppressive func-
tions within tumors, thereby hampering the development of
successful immunotherapies [8–12]. Among these, regula-
tory T cells (Treg) appear to play a critical role in the
progression of a number of cancers including breast cancer
[13–17]. Even if tumor-speciﬁc effector cells are initially
recruited into the tumor, the recruitment of Treg cells into
the same site can result in an unproductive anti-tumor
response, and this is believed to play a major part in the
failure of many cancer immunotherapies presently in
development [14, 18]. Furthermore, recent research in
mouse and human showed that, regardless of the overall
number of Treg cells in the tumor, the local balance of Treg
to effector T cells (Teff) is critical to the success of
immunotherapy and ultimately survival [19–22]. The
murine CT26 colon carcinoma cell line has been shown to
be a potent inducer of immunosuppressive mechanisms
[23–25] making it a good model to evaluate the interplay
between anti-tumor immunity and tumor-induced immu-
nosuppression. When injected intravenously (i.v.), CT26
cells give rise to experimental pulmonary metastasis while
mediating the inﬁltration of tumor-bearing lungs by a large
number of IL-10-secreting Treg [25]. Data described here
demonstrate that MVA-BN
-HER2 treatment induced
Th1-dominated HER-2-speciﬁc cellular and humoral
immunity, reduced the amount of Treg cells in the tumor
and altered the intratumoral balance of effector and regu-
latory T cells resulting in potent anti-tumor efﬁcacy against
CT26-HER-2 tumors. Our ﬁndings suggest that MVA-
BN
-HER2 generated an anti-tumor response in line with
the current paradigm of an ‘‘immune signature’’ [26] that
could lead to protective immunity in humans and warrants
further testing of MVA-BN
-HER2 in clinical trials.
Materials and methods
Animals, tumor cell lines, MVA-BN
-vectors
and HER2 proteins
Female BALB/c (H-2
d) mice were obtained from Harlan
Sprague–Dawley, Inc. CT26-HER-2 is a cell line derived
from an undifferentiated murine colon adenocarcinoma
that was transduced with human HER-2/neu [27]. CT26-
HER-2 cells were grown in IMDM ? 10% bovine calf
serum (Cellgro, Mediatech, VA). MVA-BN
 and MVA-
BN
-HER2 were produced for BNIT by Bavarian Nordic
(BN; Martinsried, Germany) [28]. The HER2 transgene
encodes the extracellular domains of HER-2 and a portion
of the trans-membrane domain but lacks the intracellular
domains. Furthermore, it encodes the T helper cell epitopes
p2 and p30 from tetanus toxin [2]. The HER2 protein used
in combination with CFA is similar to the protein expres-
sed by the MVA-BN
-transgene with the exception that
the trans-membrane domain (9 AA) is absent and the
protein has a C-terminal His tag.
Analysis of immune responses
Serum antibody titers and the frequency of IFN-c-produc-
ing T cells were determined by standard ELISA and ELI-
SPOT, respectively. Functionality of the T cells was tested
by in vivo CTL assay and intracellular IFN-c stain (for
details, see Online Resource ‘‘ESM_1_Materials and
Methods’’ MOESM1: Supplemental material 1.).
Immunotherapy
5E5 CT26-HER-2 cells were injected i.v. into female
BALB/c mice. On day four, mice were treated intraperi-
toneally (i.p.) with 10 lg HER2 in CFA or 5E7 TCID50 of
MVA-BN
 or MVA-BN
-HER2 unless indicated other-
wise in the Figure legend. Fourteen days after tumor
implantation, mice were euthanized, bled by cardiac
puncture, and lungs and spleens were collected. For
assessment of tumor burden, lungs were washed in PBS,
tapped dry on a tissue and weighed. The tumor burden was
calculated by subtracting the average lung weight of naı ¨ve
mice from the average lung weight of tumor-challenged
TBS-treated mice [29]. % tumor reduction was calculated
as: ((average lung weight of treated group - naı ¨ve group)/
(average lung weight of TBS-treated group - naı ¨ve
group)) 9 100.
In vivo depletions
Mice were injected i.p. with 100 lg of anti-CD4 (GK1.5),
anti-CD8 (2.43), anti-CD25 (PC61) or isotype control
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123antibody starting 3 days before tumor implantation and
then every 2–3 days throughout the study. Alternatively,
250 lg of antibody was given weekly. Depletion was
conﬁrmed on days 1 and 8 (on spleens and lungs from 2
mice per group) and at the end of study when FACS
analysis was performed.
Statistical analysis
Statistical signiﬁcance between treatment groups was
evaluated by One-Way ANOVA followed by Bonferroni’s
Multiple Comparisons post-test. Log-rank test was per-
formed for survival curves.
Results
Treatment with MVA-BN
-HER2 induces potent
therapeutic efﬁcacy against established
CT26-HER-2 tumors
The immunotherapeutic efﬁcacy of MVA-BN
-HER2 was
evaluated in the CT26-HER-2 pulmonary metastasis
model. Mice were challenged i.v. with 5E5 CT26-HER-2
cells and treated 3 days later with a single dose of either
1E7 TCID50 of the parental MVA-BN
 vector, MVA-
BN
-HER2 or 10 lg of HER2 protein formulated in
Complete Freund’s Adjuvant (HER2?CFA). Control
animals received TBS. Tumor burden of all mice was
determined on day 15. As shown in Fig. 1a, lungs of TBS-
treated mice were dramatically enlarged by the growing
tumor and individual foci had already fused and were
aggressively growing throughout the lung tissue (panels b
and e). Strikingly, the lungs of animals treated with a single
dose of MVA-BN
-HER2 had very small or no visible
tumors by gross examination, and only a few small foci of
tumor cells were visible by histology (panels c and f).
While the average lung weight of tumor-challenged TBS-
treated mice was almost threefold higher than that of naı ¨ve
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Fig. 1 Therapeutic anti-tumor efﬁcacy of MVA-BN
, MVA-BN
-
HER2 or HER2?CFA. a Representative pictures (a–c) and H&E-
stained sections (409, d–f) of lungs from naı ¨ve animals (no tumor
challenge; top row) or tumor-challenged mice treated with TBS
(middle row) or 1E7 TCID50 MVA-BN
-HER2 (bottom row). b Lung
weights. Average lung weights (±SD) of each group and the % tumor
reduction are indicated at the bottom of the graph (black bars
demonstrate the median lung weight of each group). Mice were
treated on day 4 with 1E7 TCID50 MVA-BN
-HER2, MVA-BN
 or
10 lg HER2 protein formulated in CFA. Similar results were
achieved in several repeat studies. c Survival study: Mice (n = 10/
group) were challenged with 5E3 CT26-HER-2 cells on day 1 and
treated q1 week 9 4 with MVA-BN
-HER2 (1E7 TCID50) starting
on day 4 (d4, 11, 18, 25) (D4) or on day 8 (d8, 15, 21, 28) (D8). TBS
treatment was started on day 4
c
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123lungs, MVA-BN
-HER2 treatment had potent anti-tumor
activity and inhibited tumor growth by 87% (P\0.001,
Fig. 1b). In contrast, tumor burden was not statistically
different between mice of the TBS- and MVA-BN
-treated
groups, demonstrating that anti-tumor efﬁcacy was
dependent on antigen-speciﬁc responses. Treatment with
HER2?CFA showed non-statistically signiﬁcant anti-
tumor activity compared to no treatment (26% reduction in
tumor burden). Hence, therapeutic intervention with MVA-
BN
-HER2, but not with HER2?CFA (P\0.001,
Fig. 1b), resulted in the induction of protective HER-2-
speciﬁc immune responses capable of suppressing aggres-
sively growing HER-2-expressing tumors in mice. The
anti-tumor activity of MVA-BN
-HER2 was further eval-
uated by monitoring mouse survival in two different model
settings. In the ﬁrst setting, mice were challenged with 5E5
CT26-HER-2 cells as described in Fig. 1b. Under these
conditions, all control mice died by day 17 and the median
survival of MVA-BN
-HER2-treated mice was approxi-
mately 25 days (see Fig. 3c). In the second and less
aggressive setting, mice were challenged with lower tumor
cell numbers (Fig. 1c). Under the latter conditions, 70% of
mice treated with MVA-BN
-HER2 survived at least
120 dayswhentreatmentwasstartedonday4(P\0.0001).
Furthermore, when the onset of treatment was delayed to
day 8, signiﬁcant protection was still observed with a sur-
vival rate of 30% 120 days after the tumor challenge
(P\0.0011).
MVA-BN
-HER2 induces potent Th1-dominated
immune responses resulting in inﬁltration of tumor-
bearing lungs by highly activated, HER-2-speciﬁc,
CD8
?CD11c
? T cells
The modalities by which MVA-BN
-HER2 triggers pro-
tectiveimmunitywereevaluatedinimmunogenicitystudies.
AsshowninSupplementalFigures1and2,bothMVA-BN
-
HER2 and HER2?CFA treatments induced anti-HER-2
antibody and T-cell responses. However, these responses
differed qualitatively in that MVA-BN
-HER2 induced a
strongly Th1-dominated humoral response with an IgG2a/
IgG1 ratio 1,000-fold higher than in HER2?CFA-immu-
nized mice. Furthermore, treatment with MVA-BN
-HER2
induced ﬁve to tenfold higher frequencies of IFN-c-pro-
ducing,HER-2-speciﬁc Tcells than HER2?CFA treatment.
HighamountsofTNF-awerealsodetectedinsupernatantsof
HER-2 restimulated splenocytes from MVA-BN
-HER2-
treated animals, while HER2?CFA treatment induced the
production of IL-5 (Supplemental Fig. 2e). Overall, these
data are in line with the known Th1 adjuvant quality of the
MVA-BN
 vector.
To further identify the mechanism of MVA-BN
-HER2-
mediated anti-tumor activity, lymphocytes inﬁltrating the
lungsoftumor-challengedmicewerecharacterized.Themost
striking result of treatment with MVA-BN
-HER2 or MVA-
BN
 was a strong accumulation of CD8 T cells. Indeed, 27.1
and21.1%oflymphocyteswereCD8
?inMVA-BN
-HER2-
orMVA-BN
-treatedanimals,respectively.Incontrast,CD8
T cells in lungs of TBS controls or lungs from HER2?CFA-
treated animals were only marginally increased as compared
to naı ¨ve lungs (Table 1).
While treatment with both viral vectors resulted in a
high density of CD8 T cells in the lung, only MVA-BN
-
HER2 markedly increased the number of activated effec-
tor/memory CD8 T cells as measured by high CD44
expression levels (40.4%, Table 1; Fig. 2a). In contrast,
CD8 T cells from lungs treated with MVA-BN
 showed
similar levels of activation as naı ¨ve or HER2?CFA-treated
mice. Notably, CD8 T-cell activation was reduced in
tumor-bearing, TBS-treated animals, where only 7% of
CD8 T cells were CD44
high (a 53% reduction compared to
naı ¨ve animals), possibly due to immunosuppressive activ-
ities provoked by the growing tumor.
In contrast to CD8 T cells, the frequency of CD4 T cells
remained relatively similar in all groups, although it
was somewhat increased in lungs of HER2?CFA-treated
animals (Table 1). However, the frequency of effector/
memoryCD4Tcellswashighestinlungsofmicetreatedwith
MVA-BN
-HER2 (42.5%) followed by treatment with
HER2?CFA (35.7%). MVA-BN
onlymarginallyincreased
CD4 T-cell activation above levels seen induced by the
growing tumor (26.9 vs. 24.4% in TBS-treated animals).
Table 1 Immunophenotyping of tumor-inﬁltrating T cells
Cell phenotype Naive TBS MVA-BN
 MVA-BN
-HER2 HER2?CFA
% CD8
? T cells of lymphocytes
1 9.8 12.7 21.1 27.1 13.5
% CD4
? T cells of lymphocytes
1 24.5 25.5 25.4 23.2 28.9
% CD44
high of CD8
? T cells
2 14.9 7 14.7 40.4 16.3
% CD44
high of CD4
? cells
2 17.3 24.4 26.9 42.5 35.7
% NKG2D
? of CD8
?CD11c
? T cells
3 50.0 68.0 84.5 90.2 77.9
1 Percent cells have been calculated as the % of CD3
?CD4
? or CD3
?CD8
? lymphocytes.
2 Calculated as % CD44
high of all CD4
? or CD8
?
cells seen in Fig. 2 panel A.
3 Calculated as % NKG2D
? of CD8
?CD11c
? T cells (Fig. 2). Similar results were found in 4 independent studies
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Fig. 2 Immunophenotyping of
lung-inﬁltrating CD8
? T cells.
FACS analysis of CD8
? T cells
from lungs of mice treated as
described in Fig. 1b. Similar
results were achieved in 4
independent experiments using
either 1E7 or 5E7 TCID50 of
either virus. Gates a: CD3
?
lymphocytes; b and c:
CD3
?CD8
? lymphocytes.
d Functionality of p63-speciﬁc
CD8 T cells isolated from lungs
of MVA-BN
-HER2-treated
animals. Panel a Lung weight in
mg at day 11 after tumor
challenge. Panel b Intracellular
IFN-c stain after 24 h in vitro
restimulation with p63. Panel c
p63-speciﬁc in vivo CTL
activity. Lungs of 5 mice were
pooled for both assays
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123Additional phenotyping of T cells inﬁltrating the lungs
of MVA-BN
-HER2-treated animals revealed a high
proportion of CD8
?CD11c
? effector/memory cells. As
shown in Fig. 2b, 18.8% of CD3
?CD8
? T cells were
CD11c
?CD44
high. This constitutes an approximately
20-fold increase in this speciﬁc cell population compared to
naı ¨ve lungs or TBS-treated tumor-bearing animals.
CD11c
?CD44
high cells were also detectable in the lungs of
MVA-BN
 or HER2?CFA-treated animals; however, the
frequency of these cells was much lower (6.01 and 3.69%,
respectively). Furthermore, the CD8
?CD11c
?-positive T
cells found in the lung expressed NKG2D and KLRG-1, two
markers often found on activated effector cells. As shown in
panel 2 of Fig. 2b, the majority of CD8
?CD11c
? Tc e l l s
expressedNKG2Dineachofthetumor-bearinggroups,witha
maximal percentage of 90% expressing NKG2D in the lungs
of MVA-BN
-HER2-treated animals (Table 1). Interest-
ingly,theexpressionofKLRG1(amarkerofCD8
?effectorT
cells commonly induced in viral infections [30]) was speciﬁc
for CD8
?CD11c
? T cells isolated from the lungs of MVA-
BN
 or MVA-BN
-HER2-treated animals.
To measure HER-2-speciﬁc T-cell responses, lymphocytes
isolated from lungs or spleens were analyzed using a pentamer
speciﬁc for the mouse MHC class I molecule K
d loaded with
theimmunodominantHER-2peptidep63.AsshowninFig. 2c,
the growing tumor alone did not induce signiﬁcant amounts of
p63-speciﬁc CD8 T cells (TBS 0.17 vs. 0.16% in naive lungs).
In contrast, the percentage of p63-speciﬁc CD8
? T cells in the
lungs of MVA-BN
-HER2-treated animals rose markedly to
approximately 1%. Similar to the whole population of CD8
?T
cells from the lungs of MVA-BN
-HER2-treated animals,
33%ofp63-speciﬁcCD8
?TcellswereCD11c
?and43%were
CD44
high (data not shown). In comparison, only a slight ele-
vation in p63-speciﬁc CD8
? T cells was observed in the lungs
of MVA-BN
 (0.31%) or HER2?CFA-treated mice (0.33%).
Importantly, HER-2-speciﬁc CD8
? T cells appeared to accu-
mulate speciﬁcally in tumor-bearing lungs since p63 staining
was not detected above background in the spleens of any
treatmentgroup(datanotshown).Thefunctionalityofthep63-
speciﬁc CD8 T cells in the lungs of MVA-BN
-HER2-treated
mice was tested during the effector phase of the response
(6–7 days post-treatment). As shown in Fig. 2d (panel a), the
tumor burden was similar between TBS- and MVA-BN
-
HER2-treatedgroups atthis timepoint(day11). Restimulation
with the p63 peptide resulted in the production of IFN-c and
C D 1 0 7b yC D 8
? T cells only in cells from the lungs of MVA-
BN
-HER2-treated animals (Fig. 2d panel b). Furthermore,
p63-labeled target cells were killed in vivo by tumor-chal-
lenged MVA-BN
-HER2-treated animals (Fig. 2d panel c).
Notably, when non-challenged mice were treated with MVA-
BN
-HER2, p63-speciﬁc T cells could only be found in the
spleens (data not shown) but not in the lungs of this group of
mice, demonstrating that the tumor is required for the homing
of p63-speciﬁc T cells to the tumor. Taken together, these data
demonstrate that MVA-BN
-HER2 treatment led to tumor
inﬁltration by highly activated and functional (CD44
high,
NKG2D
?,K L R G 1
?), HER-2-speciﬁc, CD8
?CD11c
?T cells,
while HER2?CFA treatment preferentially activated CD4
? T
cells.
MVA-BN
-HER2 anti-tumor activity overrides
the tumor-mediated accumulation of Treg cells
in the lung
The reduced percentage of CD8
? T-cell activation in TBS-
treated animals suggested that the growing tumor exerted
immunosuppressive activities. In line with this, FoxP3 stain-
ing of lung-inﬁltrating CD4
? T cells revealed that the growth
of CT26-HER-2 tumors in the lung was accompanied by a
signiﬁcantincreaseinthepercentageofTregcellsfrom2.22%
(or10.8%ofCD4
?Tcells)innaı ¨velungsto5.79%(or26.1%
of CD4
? T cells) in tumor-bearing, TBS-treated mice
(Table 2, line 1 and 4). Treatment of tumor-challenged mice
withMVA-BN
-HER2reducedthefrequencyofTregcellsto
3.44%. In contrast, treatment of tumor-bearing animals with
MVA-BN
 affected the frequency of Treg cells only margin-
ally (4.89 vs. 5.79%), while HER2?CFA treatment slightly
increasedthefrequencyofTregcellsto6.47%oflymphocytes.
To assess how treatment affected the balance between Teff
cellsandTregcellsinthelung,theCD4
?andCD8
?effectorT
cell to Treg cell ratios were calculated (Table 2). MVA-BN
-
HER2 treatment signiﬁcantly improved the ratio of both
CD4
?Teff/Treg cells and CD8
? Teff/Treg cells. Furthermore,
the ratio of activated CD8
?CD44
high/Treg cells showed an
even more dramatic 30-fold increase in the MVA-BN
-
HER2-treated group as compared to the TBS-treated group
andaﬁvefoldincreaseascomparedtonaı ¨velungs.Treatment
withtheparentalvectorMVA-BN
moremodestlyincreased
theratioofCD8
?Teff/TregcellsandCD8
?CD44
high/Tregcells
as compared to TBS-treated mice but had little effect on
CD4
?Teff/Treg cell ratios. Treatment with HER2?CFA
increased CD4
?Teff/Treg ratios to a similar extent as MVA-
BN
 treatment but had only minor effects on CD8
? Teff/Treg
ratios. These data demonstrate that treatment with MVA-
BN
-HER2, but not with HER2?CFA, reduced the fre-
quency of tumor-induced Treg cells in the lung and more
importantly,ledtoamuchhigherratioofeffectortoTregcells,
particularly with respect to CD8
? Tc e l l s .
In vivo depletion conﬁrms that CD8
? cells are required
for the anti-tumor activity of MVA-BN
-HER2
and identiﬁes Treg cells as an immunosuppressive
mechanism induced by the tumor
To further substantiate the role of CD8
? effector and Treg
cells in this tumor model, mice were depleted of CD4
? or
24 Cancer Immunol Immunother (2012) 61:19–29
123CD8
? cells beginning just prior to tumor challenge and
throughout the entire course of the model. CD8 depletion
reduced the anti-tumor activity of MVA-BN
-HER2
treatment from 99.6 to 42.4% (Fig. 3a). This difference
was highly signiﬁcant (P\0.001) demonstrating the
importance of CD8
? effector T cells in MVA-BN
-HER2-
mediated anti-tumor efﬁcacy. However, the anti-tumor
activity of MVA-BN
-HER2 treatment was not completely
abolished by CD8 depletion, as the mean lung weight from
this group was still signiﬁcantly smaller than those of CD8-
depleted, TBS-treated mice (P\0.05). This suggests that
additional CD8-independent effector mechanisms contrib-
uted to the anti-tumor efﬁcacy.
While CD8 depletion by itself had no effect on tumor
growth (Fig. 3a), removal of CD4
? cells consistently
resulted in a signiﬁcant reduction in tumor burden even
without MVA-BN
-HER2 treatment (Fig. 3a, b). Of note,
combining CD4 depletion with MVA-BN
-HER2 treat-
ment reliably decreased the anti-tumor activity of MVA-
BN
-HER2 by 20–30% (Fig. 3a, b).
The decrease in tumor burden resulting from depletion
of CD4
? cells in the absence of treatment implied that the
increased percentage of CD4
?CD25
?Foxp3
? Treg cells
present in the tumors (row 1, Table 2) play a key role in
suppressing immune responses to the tumor. To test this
directly, CD25
? cells were depleted by administration of
an anti-CD25 mAb. CD25 depletion reduced tumor burden
to a similar extent as CD4 depletion (35 and 48%,
respectively, P[0.05, Fig. 3b). This ﬁnding conﬁrmed
that the depletion of Treg cells led to the reduction in tumor
burden in CD4-depleted mice and substantiates the sig-
niﬁcance of CD4
?CD25
?Foxp3
? Treg cells in this tumor
model. However, the data also demonstrate that depletion
of Treg cells alone does not result in effective tumor
rejection.
The observed effects of CD4 or CD25 depletion on the
therapeutic efﬁcacy of MVA-BN
-HER2 were further
distinguished by evaluating their effect on the survival
rates of tumor-challenged mice. Mice were challenged with
tumors and treated with MVA-BN
-HER2 weekly four
times in the presence or absence of CD4 or CD25 deple-
tion. All mice in the TBS group died between days 16 and
18. Treatment with MVA-BN
-HER2 signiﬁcantly pro-
longed the median survival time from 17 to 24 days with
one out of 15 mice surviving through day 60 when the
study was terminated (Fig. 3c). CD4 depletion signiﬁcantly
reduced the median survival time from 24 to 21 days
(P = 0.0081, Fig. 3c) supporting a role of CD4 effector
cells in MVA-BN
-HER2-mediated anti-tumor immunity.
In contrast, the depletion of CD25
? T cells prolonged the
median survival time from 24 to 50 days resulting in sig-
niﬁcantly better survival than treatment with MVA-BN
-
HER2 alone (P = 0.0011), presumably due to the more
complete elimination of Treg cells.
Induction of HER-2-speciﬁc CD8 T cells requires
treatment with MVA-BN
-HER2 even in the
absence of Treg cells
Phenotypic analysis revealed a treatment-independent
increase in overall CD8 T-cell activation in lungs of CD4
?-
depleted animals. Upon CD4 depletion, the percentage of
activated CD8
? T cell rose from 5.6 to 26.7% in TBS-
treated animals and from 12.8 to 29.6% in MVA-BN
-
HER2-treated animals (Fig. 4a). The effect of CD4
depletion on the ampliﬁcation of HER-2-speciﬁc CD8
? T
Table 2 Immunophenotyping of effector and regulatory T cells in the lung
Naive TBS MVA-BN
 MVA-BN
-HER2 HER2?CFA
% CD4
?FoxP3
? (Treg) of lymphocytes 2.22 5.79 4.89 3.44 6.47
% CD4
?FoxP3
- (Teff) 18.4 16.4 15.9 18.3 20.7
% CD4
? T cells of lymphocytes 20.62 22.19 20.79 21.74 27.17
%T reg of CD4
? T cells 10.8 26.1 23.5 15.8 23.8
% reduction in tumor-induced Treg (total lymphocytes)
1 25.2 65.8 -19.04
% reduction in tumor-induced Treg (of CD4
? T cells)
2 16.99 67.32 15
CD4
?Teff/Treg ratio 8.3 2.8 3.3 5.3 3.2
CD4
?CD44
high/Treg ratio 1.9 1 1.4 3 1.5
% CD8
? T cells (Teff) 8 10.4 16.9 24 11.6
CD8
? Teff/Treg ratio 3.6 1.8 3.5 7 1.8
CD8
?CD44
-high/Treg ratio 0.6 0.1 0.6 3.1 0.3
All percentages are expressed as % of lymphocytes except for % Treg of CD4
? T cells. Effector T cell (Teff) to regulatory T cell (Treg) cells ratios
were calculated from FACS data: ((% CD4
?Foxp3
- lymphocytes) or (% CD8
?lymphocytes)/(% CD4
?Foxp3
?)). Similar results were found in
four independent studies. % reduction in tumor-induced Treg cells was calculated from the (% CD4
?FoxP3
? (Treg) of lymphocytes)
1 or (% Treg of
CD4
? T cells)
2 as follows: tumor-induced Treg = TBS - naı ¨ve. % reduction = 100 - ((treatment group - naı ¨ve)/tumor-induced Treg) 9 100)
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123cells,however,wasdependentontreatmentwithMVA-BN
-
HER2. No increase in HER-2-speciﬁc CD8
? T cells was
observedinthecontextofCD4depletioninTBS-treatedmice
(Fig. 4b). In contrast, the percentage of p63-speciﬁc CD8
? T
cells reliably increased by two to threefold in lungs of CD4-
depleted animals treated with MVA-BN
-HER2 (Fig. 4b).
In contrast to the depletion of all CD4
? cells, the
functional depletion of Treg cells by treatment with anti-
CD25 antibody [31] showed only minor effects on the
activation of CD8
? T cells in TBS-treated animals
(Fig. 4a). A modest increase in the frequency of activated
CD8
? T cells from 12.8 to 19% in the lung and 14.4–31.2%
in the spleen was observed in MVA-BN
-HER2-treated
animals. Notably, the increase in p63-speciﬁc CD8
? Tc e l l s
was more pronounced in MVA-BN
-HER2-treated animals
combined with CD25 depletion than in combination with
CD4depletion(Fig. 4b),againsuggestingasupportiveroleof
CD4 T cells in MVA-BN
-HER2-mediated anti-tumor
efﬁcacy.
Discussion
Successful cancer immunotherapy has to accomplish two
goals: ﬁrst, the induction of an immune response which is
capable of killing cancerous cells; second, to combat or
reverse the inﬂammatory/immunosuppressive mechanisms
exerted by the growing tumor that lead to subsequent
down-regulation of therapy-induced responses. Pertaining
to this challenge, the anti-tumor activity of MVA-BN
-
HER2 was evaluated in a pre-clinical tumor model known
to create a strong immunosuppressive environment able to
restrain T-cell responses to both tumor-speciﬁc and
bystander antigens [23–25]. Notably, a single treatment
with MVA-BN
-HER2 showed potent anti-tumor activity
against CT26-HER-2 lung metastasis despite the unfavor-
able immunosuppressive environment. The comparison of
HER-2-speciﬁc humoral and cellular immune responses
induced by treatment of mice with MVA-BN
-HER2 or
HER2?CFA demonstrated that the MVA-BN
 vector
exerted potent Th-1 adjuvant activities. More importantly,
the quality of the immune response is a crucial factor in
cancer immunotherapy as only treatment with MVA-BN
-
HER2 resulted in protective anti-tumor immunity in this
aggressive tumor model, while treatment with HER2?CFA
A
B
C
Fig. 3 Effect of in vivo depletion of CD8
?, CD4
? or CD25
? T cells
on anti-tumor efﬁcacy. a Tumor challenge and treatments were
performed as described for Fig. 1. A single dose 5E7 TCID50 MVA-
BN
-HER2 was given on day 4. CD4 or CD8 T cells were depleted
by i.p. injection of anti-CD4, anti-CD8, anti-CD25 or isotype control
antibody. Treatment with isotype control Ab had no effect on tumor
growth (data not shown). CD4 and CD8 T-cell depletion was
conﬁrmed by FACS analysis (days 1, 8 and 15). Depletion was 100%
complete throughout the study. Similar results were achieved in three
independent studies. b Separate experiment evaluating the role of
CD25
? T cells. Similar results were achieved in two independent
studies. c Survival study: Mice (n = 15/group) were challenged with
tumors on day 1 as described before and treated q1 week 9 4 (days 4,
11, 18 and 25) with TBS or MVA-BN
-HER2 (1E7 TCID50)
combined with CD4 or CD25 depletion. Antibodies were given on
days -4, 3, 10, 17 and 24 at 250 lg/dose. Statistical analysis was
performed by log-rank test
c
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123did not. Anti-tumor activity was accompanied by a high
densityofactivatedCD8
?Tcellsalongwithaclearreduction
in the percentage of Treg cells in the lungs of animals treated
with MVA-BN
-HER2,thusresulting in a crucialshift inthe
balance of Teff to Treg cells in favor of effector T cells [22].
Importantly, the tumor-inﬁltrating HER-2-speciﬁc CD8 Teff
cellswerefunctionalasdemonstratedbyinvivoCTLactivity
and intracellular IFN-c production. These cells were found in
the spleen in MVA-BN
-HER2-treated non-challenged ani-
mals and homed to the lungs in tumor-challenged mice.
Immunotherapy with MVA-BN
-HER2 also showed a sig-
niﬁcant anti-tumor efﬁcacy in a solid CT26-HER2 tumor
model (see Supplemental Fig. 3). In this model, epitope
spreadingtoothertumor-associatedantigensandlong-lasting
CTL memory was demonstrated.
A high percentage of CD8 T cells found in lungs of
MVA-BN
-HER2- or MVA-BN
-treated mice expressed
the markers CD11c, NKG2D and KLRG1. The expression
of the myeloid marker CD11c on CD8 T cells has been
described following acute infections with several viruses
including vaccinia [32]. In general, all CD8
?CD11c
? T
cells also expressed elevated levels of CD44 and have been
described in virally infected mice as activated, virus-spe-
ciﬁc, cytotoxic T cells that are much more effective at
controlling viral infections than CD8
? T cells negative for
CD11c [32–34]. Interestingly, CD8
?CD11c
? T cells have
also been identiﬁed as effectors of anti-4-1BB-mediated
tumor suppression in several mouse tumor immunotherapy
models using agonistic anti-4-1-BB antibodies [35–37].
Similar to the results described here, both NKG2D and
KLRG-1 were highly expressed on anti-4-1-BB-induced
CD8
?CD11c
? T cells, and they preferentially accumulated
in the tumor tissue. Together, these data suggest that
CD8
?CD11c
? T cells found in tumor-bearing lungs are a
mixture of highly activated MVA virus- or tumor-speciﬁc
CD8
? effector/memory T cells.
The lung in particular is an immunosuppressive envi-
ronment in which the constitutive production of IL-10 is
necessary to protect the integrity of the delicate and highly
vascularized tissue. Growing CT26 tumors enhance this
already immunosuppressive environment resulting in the
recruitment of CD4
?CD25
?FoxP3
? Treg cells [25]. Natural
CD4
?CD25
? Treg play a critical role in the progression of a
number of cancers [17] and are believed to play a major
part in the failure of many immunotherapies against tumors
in mice [24, 38–40] and men [18]. We found that the
presence of CT26-HER-2 tumors in the lung consistently
increased the percentage of Treg cells by approximately
threefold. The fact that a single treatment with MVA-BN
-
HER2 signiﬁcantly reduced the frequency of Treg cells by
up to 70% demonstrates that treatment with MVA-BN
-
HER2 can override the potent effects of CD4
?CD25
?
FoxP3
? Treg cells in establishing conditions conducive to
tumor growth, even in the immunosuppressive environ-
ment of the lung. In stark contrast, treatment with
HER2?CFA resulted in a further increase in the percent-
age of Treg cells in the lung and failed to induce any sig-
niﬁcant anti-tumor efﬁcacy in this model. In vivo depletion
experiments further conﬁrmed that the importance of Treg
cells in this tumor model as depletion of either CD4
? T
cells or CD25
? T cells resulted in a similar partial reduc-
tion in tumor burden. MVA-BN
-HER2 therapy was
necessary for the expansion of p63-speciﬁc CD8 T cells in
both CD4- and CD25-depleted animals, demonstrating that
the tumor alone was not able to induce HER-2-speciﬁc T
cells even in the absence of Treg cells. However, pheno-
typic analysis of lung-inﬁltrating T cells from mice
depleted of either CD25
? or CD4
? T cells revealed inter-
esting differences. While CD4 depletion resulted in an
increase in CD8 T-cell activation irrespective of treatment
with MVA-BN
-HER2, the depletion of CD25
? cells only
increased CD8 T-cell activation in MVA-BN
-HER2-
treated mice. Although the increased activation of CD8 T
cells could be responsible for the reduced tumor burden
-- -- wt wt
-- -- wt wt
A
B
Fig. 4 Effect of CD4 or CD25 depletion on CD8 T-cell activation
and frequency of HER-2-speciﬁc CD8 T cells. Animals were treated
as described in legend to Fig. 3a, b. On day 15, single-cell
suspensions were prepared from lungs and spleens for FACS analysis.
a Percent of activated CD8
?T cells in lung (black bars) and spleen
(gray bars). b Percent K
d p63 pentamer
? cells of CD8
? T cells;
similar results were achieved in three independent studies
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123observed in CD4-depleted mice, it is unlikely that CD8
? T
cells are responsible for the reduced tumor size observed in
TBS-treated CD25-depleted mice. This could suggest that
the absence of Treg cells might relieve immunosuppressive
mechanisms that allow for the activation of cell types other
than CD8 T cells. Two likely candidates are CD4 T cells or
innate immune effector cells such as NK cells. We are
currently investigating the role of CD4 T cells and innate
immune mechanisms in MVA-BN
-HER2-mediated anti-
tumor efﬁcacy.
In cancer immunotherapy, a broad response involving
all arms of the immune system is desired. Repeated treat-
ment of mice with MVA-BN
-HER2 resulted in the
induction of robust anti-HER-2 antibody responses (sup-
plemental data Fig. 1). Using trastuzumab as a standard,
we determined that these titers correlate with 50–500 lg
HER-2-speciﬁc antibody/mL serum (data not shown), a
level within the range of that found in patients treated with
trastuzumab [41, 42]. Although HER-2-speciﬁc antibodies
do not seem to play a protective role in this particular
mouse tumor model, they can be important in other models
(our own unpublished observations) and a role for anti-
body-mediated rejection of HER-2-positive tumors has
been well established by the therapeutic activity of trast-
uzumab. Several other monoclonal antibodies have also
demonstrated clinical effectiveness in a variety of malig-
nancies through mechanisms such as antibody-dependent
cell-mediated cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) [43, 44]. Antibody response
induced by MVA-BN
-HER2 showed a strong Th1 bias
with IgG2a to IgG1 ratios 500- to 1,000-fold higher than in
mice immunized with HER2?CFA. Since Th1 isotypes are
thought to be the most efﬁcient mediators of ADCC and
CDC, the humoral responses produced by MVA-BN
-
HER2 treatment are desirable and may provide therapeutic
activity in human patients.
In conclusion, the data presented here demonstrate that a
single treatment with MVA-BN
-HER2 was able to
simultaneously induce Th1-dominated HER-2-speciﬁc
immune responses and control tumor-induced immuno-
suppression resulting in potent anti-tumor efﬁcacy. These
preclinical results and the excellent safety proﬁle and
immunogenicity of MVA-BN
 even in immune-compro-
mised patients (4–6) provide further support for the
development of MVA-BN
-HER2 for cancer immuno-
therapy. Notably, the immune responses induced by
immunotherapy with MVA-BN
-HER2 are in line with a
recently described distinct ‘‘immune signature’’ necessary
for the inhibition of a variety of solid tumors treated with
different immunotherapeutic strategies including breast
cancer [26, 45–48]. Two hallmark features of this signature
are the generation of a tumor-speciﬁc Th1 responses and a
high density of T cells in the tumor parenchyma. The
ability of MVA-BN
-HER2 to induce HER-2-speciﬁc
immune responses in humans is currently being assessed in
Phase I/II clinical trials in HER-2-positive breast cancer
patients (NCT00485277).
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